Provider Bulletin # 18-09
Diagnostic Laboratory Services in Outpatient Drug and Alcohol Clinics
Frequently Asked Questions (FAQ)

1. **When will this change go into effect?**
   This change will go into effect September 17, 2018.

2. **Do the changes in lab screenings apply to urine drug screens (UDS) only, or do they also apply to bloodwork (complete blood counts (CBC), lipids, etc.)?**
   The changes apply to all lab screens that are completed to detect/identify and confirm the use of substances.

3. **Does this change apply to suboxone providers as well?**
   This change applies to all Substance Abuse and Mental Health Services Administration (SAMHSA) Opioid Treatment Provider /Narcotic Treatment Provider (OTP/NTP) providers.

4. **Will rate enhancements include coverage for required confirmations?**
   Yes, the rate enhancements will include coverage for required confirmations.

5. **Will CBH notify the labs of these changes?**
   Yes, CBH is communicating with the CBH-contracted labs regarding the changes.

6. **Which labs does CBH contract with?**
   CBH contracts with Quest Diagnostics Clinical Labs, Atlantic Diagnostic Labs, and Parkway (Almarc) Clinical Labs.

7. **Will the rate adjustment go into effect on September 17, 2018 as well?**
   Yes. The new rate will be reflected on your schedule A as effective September 17, 2018.

8. **The Bulletin states that CBH will monitor for compliance. What exactly will CBH be monitoring?**
   CBH will be monitoring to ensure that members are continuing to receive the minimal required UDS screens that are clinically indicated.

9. **How did CBH determine that at minimum there should be 16 UDS per year?**
   Based on the average number of UDS administered to members receiving medication-assisted treatment (MAT) in the last year.

10. **What if a provider completes a UDS and it is determined that the member is not appropriate for the MAT program, and is not induced; will CBH cover the cost of the UDS?**
    Yes, CBH will cover the cost of the UDS in this scenario.